| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 54% | $924,853,728 | 17,095,263 | Lin Bioscience International Ltd. | 31 Dec 2024 | |||
| Darwin Global Management, Ltd. | 7% | $339,227,724 | 2,617,094 | Darwin Global Management, Ltd. | 03 Dec 2025 | |||
| Lin Yu-Hsin | 7.1% | $123,730,487 | 2,287,070 | Yu-Hsin Lin | 31 Dec 2024 |
As of 30 Sep 2025, 34 institutional investors reported holding 2,288,469 shares of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE). This represents 6.1% of the company’s total 37,387,057 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 6,933 | $1,109,313 | +$828,103 | $159.96 | 3 |
| 2025 Q3 | 2,288,469 | $169,346,585 | +$162,953,207 | $74.00 | 34 |
| 2025 Q2 | 78,139 | $4,508,619 | -$5,101,965 | $57.70 | 18 |
| 2025 Q1 | 149,657 | $9,909,658 | -$8,038,751 | $66.22 | 18 |
| 2024 Q4 | 282,406 | $17,820,740 | +$12,809,959 | $63.10 | 21 |
| 2024 Q3 | 78,699 | $3,689,407 | -$4,872,726 | $46.88 | 15 |
| 2024 Q2 | 186,568 | $8,522,342 | +$5,980,160 | $45.68 | 11 |
| 2024 Q1 | 58,112 | $2,229,758 | -$3,456,843 | $38.37 | 11 |
| 2023 Q4 | 5,200 | $237,900 | +$237,900 | $45.75 | 1 |
| 2023 Q3 | 99,593 | $3,165,868 | -$26,250,077 | $31.85 | 7 |
| 2023 Q2 | 1,040,502 | $14,866,363 | +$2,374,159 | $14.29 | 6 |
| 2023 Q1 | 850,185 | $25,389,513 | -$211,069 | $29.90 | 8 |
| 2022 Q4 | 857,329 | $25,861,711 | +$22,306,676 | $30.15 | 7 |
| 2022 Q3 | 115,088 | $3,870,578 | +$1,586,625 | $33.76 | 8 |
| 2022 Q2 | 68,935 | $2,146,000 | +$2,146,001 | $31.13 | 6 |